ReviewFrontiers in bioengineering and biotechnology2020
Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- The Role of Genetically Engineered Probiotics for Treatment of Inflammatory Bowel Disease: A Systematic Review.Nutrients · 2023Pooled it
- Serological Biomarkers and Diversion Colitis: Changes after Stimulation with Probiotics.Biomolecules · 2021Trial
- Gut microbiome dynamics in acute infectious diarrhea: A conceptual framework from acute dysbiosis toward precision restoration (Review).Experimental and therapeutic medicine · 2026Review
- Review
- Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Promising Future of Engineered Probiotics for Antimicrobial Peptides and Protein Production: Prospects and Industrial Challenges.Probiotics and antimicrobial proteins · 2026Review
- Redrawing the gut map: evolving probiotic approaches to microbiota modulation in inflammatory bowel disease.Antonie van Leeuwenhoek · 2026Review
- Therapeutic Potential of Probiotics: A Review of Their Role in Modulating Inflammation.Probiotics and antimicrobial proteins · 2026Review
- The gut microbiome in colorectal anastomotic leakage: from mechanisms to precision.Frontiers in medicine · 2026Review
- The impacts of native potential probiotic cocktail to prevent or ameliorate inflammation by targeting autophagy signalling pathway.Journal of nutritional science · 2026Article
- Biosensors for Cancer and Inflammation: Whole-Cell Biosensors for Soluble Molecules.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Systems biology and microbiome innovations for personalized diabetic retinopathy management.NPJ systems biology and applications · 2025Review
- Genetically Engineered Probiotics: Design, Therapeutics, and Clinical Translation.Iranian biomedical journal · 2025Review
- The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook.ACS applied bio materials · 2025Review
- Probiotic acoustic biosensors for noninvasive imaging of gut inflammation.Nature communications · 2025Article
- Evaluation of Engineering Potential in Undomesticated Microbes With VECTOR.Microbial biotechnology · 2025Article
- Biosensors in Microbial Ecology: Revolutionizing Food Safety and Quality.Microorganisms · 2025Review
- Motile and Chemotactic Minicells and Minicell-Driven Biohybrids Engineered for Active Cargo Delivery.ACS applied materials & interfaces · 2025Article
- Exploring the gut microbiome's influence on cancer-associated anemia: Mechanisms, clinical challenges, and innovative therapies.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory intestinal diseases such as Crohn's disease and ulcerative colitis have seen an increase in their prevalence in developing countries throughout the current decade. These are caused by a combination of genetic and environmental factors, altered immune response, intestinal epithelium disruption and dysbiosis in the gut microbiome. Current therapies are mainly focused on treating symptoms and are often expensive and ineffective in the long term. Recently, there has been an increase in our understanding of the relevance of the gut microbiome and its impact on human health. Advances in the use of probiotics and synthetic biology have led to the development of intestinal biosensors, bacteria engineered to detect inflammation biomarkers, that work as diagnostic tools. Additionally, live biotherapeutics have been engineered as delivery vehicles to produce treatment
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.